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Background/aim: The purpose of this study was to evaluate the concordance of immunohistochemical (IHC) parameters of breast
lesions between the core needle biopsy (CNB) and the surgical resection specimen.
Materials and methods: CNB and resection specimens of female patients were retrospectively analyzed. ER, PR, HER-2, and Ki-67
parameters were compared for each patient. A total of 284 cases were assessed. Forty-one and 48 cases were excluded from the HER-2
and Ki-67 examinations, respectively, because the CNBs did not allow for IHC.
Results: Concordance rates were 93.3% for ER, 89.4% for PR, 90.1% for HER-2, and 80.9% for Ki-67.
Conclusion: CNB is accurate for the evaluation of the surrogate molecular profile of invasive breast cancer despite the heterogeneity of
tumors.
Key words: Breast cancer, image-guided biopsy, immunohistochemistry, Ki-67, hormone receptors, c-erb-B2

1. Introduction
Core needle biopsy (CNB) is a reliable method that is
widely used for preoperative diagnosis of breast cancer
and specification of prognostic and predictive parameters
(1–3). Neoadjuvant systemic therapy can be organized
with the guidance of CNB (2). For cases with complete
remission after neoadjuvant systemic therapy, CNB can
be the only method that reflects the characteristics of the
tumor (4–6). On the other hand, CNB is a useful tool for
the diagnosis and management of sentinel lymph node
metastasis (7) and distant metastasis (8). In addition to
its diagnostic and predictive role in breast cancer, CNB
is used to support patients’ education, cooperation, and
consent (9). In spite of its advantages, CNB may not
completely represent the biological profile of the tumor
in all cases, resulting from not only methodological
limitations but also intratumoral heterogeneity (10).
Numerous studies investigated the disparity between
the CNB and resection specimen (RS) results and
reported different findings. Diagnosis of breast carcinoma
was reported to be concordant in 96% to 100% of cases
in a previous study (11). Accuracy of estrogen receptor
(ER), progesterone receptor (PR), and human epidermal
* Correspondence: erdemkombak@hotmail.com

growth factor receptor 2 (HER-2) status has been found
to range from 77.8% to 100% for ER, 69% to 97.1% for PR,
and 60% to 98% for HER-2 in the literature (8). For Ki67, the criteria for subclassification of breast carcinomas
are yet to be defined, although a few suggestions of
cutoffs have been made. Our purpose in this study is
to assess the concordance of immunohistochemical
assessment of the surrogate molecular profile of tumors
by comparing CNBs and RSs and to clarify the reasons
for discrepancies.
2. Materials and methods
2.1. Patients
Among the female patients who were admitted to our
hospital with the diagnosis of operable invasive breast
cancer between December 2011 and December 2015, the
ones with a record of both CNB and RS were assessed
retrospectively in this study. Male patients, patients who
received neoadjuvant chemotherapy, and patients who
had their pathology reviewed only in our hospital were
excluded. Characteristics of the largest tumor were taken
into account while assessing the cases with more than
one tumor focus.
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2.2. Immunohistochemistry (IHC)
CNBs or RSs were kept in neutral buffered formalin
overnight, providing an optimum fixation time between
6 and 72 h, then embedded in paraffin, as suggested
by the ASCO/CAP testing guidelines (3,10,12,13).
Immunohistochemical staining was performed on sections
of 4 µm with the Bond-Max autoimmunostainer (Leica
Biosystems, Nussloch, Germany) by using ER antibody
at 1:100 (Clone 6F11 mouse monoclonal antibody, Leica
Biosystems, Newcastle, United Kingdom), PR antibody
at 1:100 (Clone 16 mouse monoclonal antibody, Leica
Biosystems), HER-2 antibody at 1:100 (Clone 10A7 mouse
monoclonal antibody, Leica Biosystems), and Ki-67
antibody at 1:100 (Clone K2 mouse monoclonal antibody,
Leica Biosystems).
The IHC slides were assessed as part of the daily routine
by two pathologists, one of whom was an experienced
consultant for breast pathology. The cutoff point for ER
and PR positivity was set at 1% (Figures 1 and 2). HER-2
overexpression was scored as 1+ (incomplete membrane
staining in any proportion of tumor cells), 2+ (complete
membrane staining that was either nonuniform or weak
in intensity but with obvious circumferential distribution
in at least 10% of tumor cells, or invasive tumors with
intense, complete membrane staining of 10% or fewer
tumor cells), or 3+ (uniform, intense membrane staining
of 10% of invasive tumor cells) in accordance with the
ASCO/CAP guidelines (10) (Figures 3 and 4). For Ki-67
assessments, the slides were scanned at low magnification
(100×) to identify and encircle the hot-spot (HS); this was
defined as the area containing the highest density of Ki67-labeled tumor cells by visual impression. Tumor cells
in consecutive high power fields were counted in HSs. Any
nuclear staining regardless of intensity was considered
positive and the percentage of positive tumor cells was

Figure 1. Intratumoral heterogeneity of PR immunoreactivity
(100×).
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Figure 2. Intratumoral heterogeneity of PR immunoreactivity
(400×).

recorded. A cutoff point of 14% was used, in regards to
the 2011 St Gallen International Expert Consensus (14).
All results were assessed overall and in separate groups
for histologic type, tumor grade, and pathological tumor
stage. Groups were as follows: ductal (DC), lobular (LC),
and mixed & other (MO) for histologic type; grade 1 (G1),
grade 2 (G2), and grade 3 (G3) for tumor grade; and pT1,
pT2, pT3, and pT4 for pathological stage.
2.3. Statistical analysis
The chi-square test was applied to compare the diagnoses
and immunohistochemical findings of ER, PR, HER-2,
and Ki-67 stains across paired CNB and RS samples using
SPSS 15. P < 0.05 was considered statistically significant.
3. Results
Records of 473 patients with RSs were collected. CNB
was performed for only 307 (65%) of them. Among those

Figure 3. Intratumoral heterogeneity of HER-2 immunoreactivity
(100×).
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Figure 4. Intratumoral heterogeneity of HER-2 immunoreactivity
(400×).

307 cases, 12 were diagnosed as carcinoma in situ, 3
were diagnosed as microinvasive carcinoma, and 8 were
diagnosed as benign changes. After excluding them, a
total of 284 cases were assessed. Forty-one and 48 cases
were excluded from the HER-2 and Ki-67 examinations,
respectively, because the CNBs did not allow for IHC.
Mean age was 52.3 with the range of 22–84 years.
Tumor characteristics are listed in Table 1. Seven cases
diagnosed as ductal carcinoma in CNB were discerned
to be lobular carcinoma based on the RS. This subset of
discrepancy accounted for 2.5% of all cases. There was no

mismatch between benign/in situ/malignant lesions, quite
likely due to clinical-radiological-pathological correlation
meeting provisions.
Overall ER was positive in 87.3% of CNBs and 82.7%
of RSs (P < 0.001). There was discrepancy in 19 cases and
the concordance was 93.3%. Sixteen of the discrepant cases
were ER-positive in CNB and ER-negative in RS. Three
cases were ER-negative in CNB and weakly ER-positive in
RS. Concordance for separate groups is shown in Table 2.
PR was positive in 80.6% of CNBs; however, it was
positive in 75.7% of RSs (P < 0.01). The overall concordance
was 89.4% with discrepancy in 30 cases. Eight cases that
were PR-negative in CNB were PR-positive in RS. On the
other hand, 22 discrepant cases were PR-positive in CNB
and PR-negative in RS. Concordance for separate groups
is shown in Table 2.
HER-2 IHC was found positive in 18.9% of CNBs
and 18.5% of RSs (P < 0.01). There were 24 discrepant
cases, and the overall concordance was 90.1%. Eleven of
discrepant cases were HER-2-negative in CNB, although
they were HER-2-positive in RS. The other 13 discrepant
cases were HER-2-positive in CNB and negative in RS.
Concordance for separate groups is shown in Table 2.
The Ki-67 proliferation index was <14% in 36.9% of
CNBs, <14% in 34.8% of RSs, ≥14% in 63.1% of CNBs,
and ≥14% in 65.2% of RSs. There were a total of 45
discrepant cases, and the overall concordance was 80.9%.
Concordance for separate groups is shown in Table 2.
Histologic grade was estimated only for RSs. Thirty
(10.6%) cases were grade 1, while 130 (45.8%) and 124

Table 1. Characteristics of tumors included in the study, n (%).
Characteristics of tumors
Number of
discordant cases

CNB

RS

Ductal
Lobular
Mixed and other

245 (86.3%)
8 (2.8%)
31 (12.5%)

205 (72.2%)
17 (5.9%)
62 (21.8%)

ER

+

36 (12.6%)
248 (87.3%)

49 (17.2%)
235 (82.7%)

P < 0.001

PR

+

55 (19.3%)
229 (80.6%)

69 (24.3%)
215 (75.7%)

P < 0.001

Her-2

0
1
2
3

159 (65.4%)
16 (6.6%)
22 (9%)
46 (18.9%)

169 (69.5%)
14 (5.8%)
15 (6.2%)
45 (18.5%)

P < 0.001

Ki-67

<14 %
≥14 %

87 (36.9%)
149 (63.1%)

82 (34.8%)
154 (65.2%)

P < 0.001

Histologic
subtype

19
30

24

45
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Table 2. Concordance of IHC parameters within subgroups, n (%).
ER con.

PR con.

HER-2 con.

Ki-67 con.

DC

195 (95.1%)

183 (89.3%)

155 (87.6%)

141 (81%)

LC

17 (100%)

17 (100%)

15 (93.8%)

10 (62.5%)

MO

53 (85.5%)

52 (83.9%)

49 (96.1%)

40 (85.1%)

G1

28 (93.3%)

28 (93.3%)

23 (92%)

18 (82%)

G2

124 (95.4%)

121 (93.1%)

96 (88.9%)

82 (75.6%)

G3

111 (89.5%)

105 (84.7%)

99 (90%)

92 (86%)

pT1

102 (96.2%)

103 (97.2%)

81 (92%)

68 (80%)

pT2

148 (91.9%)

142 (88.2%)

127 (89.4%)

115 (83.3%)

pT3

11 (91.7%)

11 (91.7%)

9 (83.3%)

7 (66.7%)

pT4

5 (100%)

5 (100%)

2 (50%)

2 (50%)

con.: Concordance, DC: ductal carcinoma, LC: lobular carcinoma, MO: mixed and other, G:
grade, pT: pathologic stage of tumor.

(43.7%) cases were grade 2 and 3, respectively. In this
study, we noted pT and pN statuses as markers of tumor
size and regional lymph node involvement, as summarized
in Table 3.
4. Discussion
As breast cancer is the most frequently diagnosed cancer
and the second most frequent cause of cancer-related death
in women, preoperative assessments of diagnosis and of
prognostic factors are becoming more and more important
steps in the management of patients. CNB is a routinely
used method for preoperative assessment of breast cancer
patients (1–3,5). CNB may not completely represent the
biological profile of the tumor in all cases because of
sampling errors (15), insufficient sample size of the CNB,
fixation problems of RSs, intratumoral heterogeneity, and
menopausal status of patients (3,5,8,9). The aim of this
study was to assess the concordance of CNB and RS results
and to clarify the reasons for discrepancies.
Table 3. Tumor size and regional lymph node involvement, n
(%).
pT

pN

1794

1

106 (37.3%)

2

161 (56.7%)

3

12 (4.2%)

4

5 (1.8%)

X
0
1
2
3

9 (3.2%)
154 (54.2%)
83 (29.2%)
24 (8.5%)
14 (4.9%)

Concordance rates between CNB and RS were found
as 93.3%, 89.4%, 90.1%, and 80.9% for ER, PR, HER-2, and
Ki-67, respectively, in this study. In our multidisciplinary
algorithm, cases lacking clinical-radiological-pathological
correlation are considered “sampling errors” and submitted
to repeat biopsies, which resulted in a lack of mismatch
for benign/in situ/malignant diagnoses between CNBs
and RSs. In the literature, concordance rates of ER, PR,
and HER-2 have been found to range between 77.8% and
100% for ER, 69% and 97.1% for PR, and 60% and 98% for
HER-2 (6,8). We noted a higher concordance rate for ER
than PR, a pattern that has been described in the literature
(1,5). Concordance rates of ER for separate groups were
close. PR concordance is highest in the LC, G2, and pT4
groups. PR concordance was seemingly close in separate
groups. Cases with ER/PR/HER-2-positive tumors in the
CNB may not be restained upon RS (16), since a negative
result in RS would only change the estimated effectivity of
the given neoadjuvant and/or adjuvant therapy (17–20).
On the other hand, our own experience is that cases with
ER/PR/HER-2-negative tumors in CNB must be restained
upon RS, especially in the case of contrast between CNB
and RS regarding histologic grade, growth pattern, and
concomitant inflammatory infiltration.
As tumor size scaled up, Ki-67 concordance tended
to decrease, whereas the histologic type and tumor
grade were not different at all. The concordance of the
Ki-67 proliferation index is controversial (21,22), since it
is easily affected by many factors such as surgical time
interval (23), cold ischemic time (24), prior biopsy size,
heterogeneity of histologic grade (25) fixation time
despite controversies (26), and interobserver variation.
After the suggestion of Ki-67 as a predictive marker
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for adjuvant chemotherapy, interobserver variation
and methodological issues have been increasingly
discussed (27,28). Some recommendations for Ki67 assessment were presented in 2011 and the lack
of systematic comparisons of Ki-67 expression levels
between tissue microarrays and whole sections was
noted (27). As an example, the Ki-67 cutoff point of
14%, recommended for treatment decisions by the St
Gallen 2011 guidelines, was based on data from a series
of tissue microarrays combined with gene expression
analysis (29). However, the clinical implications of these
findings have not been well documented. In this study, we
found a slight difference in proliferation with median Ki67 positivity of 15% for CNBs and 20% for RSs. However,
there were a total of 55 discordant cases, which is rather
high compared to the discordance rates for ER/PR and
HER-2.

We investigated the concordance of diagnostic and
prognostic parameters between CNBs and RSs in 284 breast
cancer patients’ paired samples, which is one of the largest
series published so far on the subject. Although concordance
rates of ER, PR, HER-2, and Ki-67 statuses were high in this
study, similar to the published literature, notable differences
between CNB and RS were found (30). These differences were
found to be primarily due to intratumoral heterogeneity.
In conclusion, our study indicates that CNB is
accurate for the evaluation of predictive and prognostic
immunohistochemical markers of invasive breast
cancer despite the heterogeneity of tumors. The
immunohistochemical evaluation of these markers does
not need to be repeated on RS, unless there is negativity in
CNB or the biopsy is inadequate. Repeat tests are needed
on RSs in such cases to prevent patients from missing the
chance of potential targeted therapy.
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